+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 52 Actively Recruiting clinical trials

E

Actively Recruiting

This research aims to evaluate the efficacy and safety of rilzabrutinib in adults diagnosed with active Immunoglobulin G4-related disease IgG4-RD. It is a Phase 3, randomized, double-blind, placebo-controlled study that will measure the time to clinical disease flare and other important efficacy and safety outcomes over a 52-week treatment period. The study includes adult participants aged 18 and older who have a confirmed diagnosis of IgG4-RD and active disease in at least one organ. Participants will be randomly assigned to receive either rilzabrutinib tablets or a placebo, both taken orally, over a 52-week double-blind treatment period. The study also includes a screening period of 4 to 6 weeks before treatment, followed by a 2-week follow-up after the treatment phase. An optional open-label extension lasting 108 weeks is available for participants who complete the main study. The total study duration may extend up to 60 weeks for the main phases. Throughout the study, participants will attend up to 16 visits during the main treatment period and additional visits if they join the extension phase. Researchers will monitor disease activity and flare rates using clinical assessments, imaging procedures such as CT, MRI, PET, or ultrasound, laboratory tests, ECGs, and safety evaluations including adverse event monitoring. Outcomes include flare-free rates, disease activity scores, glucocorticoid use, and safety parameters, with follow-up continuing beyond the treatment phase to assess long-term effects.

Age: 18Years +All GendersPhase 3
95 locations
T

Actively Recruiting

Healthy Volunteer

Researchers are evaluating CPV-104, a new medicine designed to regulate the complement system, which may be overactive in C3 glomerulopathy C3G, an ultra-rare kidney disorder. This phase 1 trial is the first time CPV-104 is tested in humans, including both healthy adults and adults with C3G. The study aims to assess safety, tolerability, how the body processes the medicine, and immune system reactions. The trial has two parts Part 1 involves healthy volunteers receiving a single intravenous dose of CPV-104 or placebo in a randomized, double-blind setting. Part 2 involves patients with C3G receiving four weekly intravenous doses of CPV-104 without placebo. Dose escalation depends on safety reviews. All treatments are given by healthcare professionals. Participants will be closely monitored through side-effect checks, blood and urine tests, ECGs, vital signs, and blood samples to measure drug levels and antibodies. For C3G patients, kidney function will also be observed. Safety Review Committee regularly reviews data to ensure participant safety. The study measures severe and serious adverse drug reactions up to 29 days for healthy volunteers and up to 50 days for C3G patients.

Age: 18Years +All GendersPhase 1
17 locations
L

Actively Recruiting

Researchers are evaluating a lifestyle intervention aimed at improving health habits and reducing cardiometabolic risk factors in adults with obsessive-compulsive disorder OCD. This condition is linked to higher risks of heart and metabolic diseases, partly due to unhealthy lifestyle behaviors. This trial is the first randomized controlled study to assess the effectiveness and cost-efficiency of such an intervention for people with OCD. Participants are randomly assigned to one of two groups. The first group receives a 13-week lifestyle program including one personal session to set goals, followed by 12 weekly group sessions combining education on healthy habits and physical exercise. After these sessions, they get access to a digital booster module to maintain changes. The second group receives one individual session with feedback on their health and written advice on healthy lifestyle habits based on national guidelines. During the study, participants will wear accelerometers to measure physical activity, and assessments will take place at the start, after 14 weeks, and at 12 months to track changes in activity, diet, mental health, and cardiometabolic markers. Questionnaires and physical measurements will be used to evaluate outcomes such as stress, sleep, OCD symptoms, quality of life, and various blood tests. Safety and cost-effectiveness will also be monitored throughout the trial period.

Age: 18Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
P

Actively Recruiting

Researchers are evaluating the safety and tolerability of Karonudib, an oral drug, for treating patients with advanced blood cancers including Acute Myeloid Leukemia AML, Acute Lymphoblastic Leukemia ALL, Diffuse Large B-Cell Lymphoma DLBCL, Multiple Myeloma MM, high-risk Myelodysplastic Syndrome MDS, and Burkitts lymphoma. The study also aims to find a recommended dose and schedule for further development, understand how the drug is processed in the body, and look for early signs of treatment effect. Overall survival of patients will also be recorded during the trial. The study includes a dose escalation phase where Karonudib is given as an oral solution every other day in three planned dose groups. An extension phase involves Karonudib taken twice a week together with standard care treatment Idarubicin on days 1 to 3. Patients will receive the drug orally and the study is designed sequentially to evaluate safety and tolerability first before further phases. This is a Phase 1 interventional study focused on treatment. Participants will be monitored closely for safety and tolerability during the first 28-day treatment cycle, which is the primary outcome period. Researchers will collect blood and bone marrow samples or imaging to measure disease and treatment response. Additional assessments include heart function, liver and kidney tests, and pregnancy tests for women of childbearing potential. The trial lasts until April 2027 and includes repeated assessments to understand the drugs effects and patient survival.

Age: 18Years - 75YearsAll GendersPhase 1
7 locations
P

Actively Recruiting

Researchers are evaluating AZD0120, a dual targeting CAR T-cell therapy that targets BCMA and CD19, in adults with autoimmune diseases including systemic sclerosis, idiopathic inflammatory myopathies, and difficult-to-treat rheumatoid arthritis. This Phase 1b2 open-label study is designed to assess the safety and tolerability of AZD0120 in these conditions. The trial is sponsored by AstraZeneca and conducted at multiple centers. Participants will receive one of several treatment regimens an infusion of AZD0120 or one of two standard-of-care SOC regimens for rheumatoid arthritis. Each participant will follow the assigned treatment plan according to their cohort. The study evaluates responses at various time points including baseline, week 12, and week 52 to monitor disease activity and treatment effects. Throughout the study, participants will undergo regular assessments including monitoring for dose-limiting toxicities and adverse events for up to one year. Disease activity will be measured using various clinical scores such as the Revised-CRISS response, Disease Activity Score 28 C reactive protein DAS28-CRP, and patient-reported outcomes. Cellular kinetics and immune response markers will also be tracked. Participants are monitored closely during treatment and follow-up periods lasting up to one year after treatment.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
25 locations
E

Actively Recruiting

Researchers are studying the effects of elritercept TAK-226, KER-050 in treating anemia in adults with very low, low, or intermediate-risk myelodysplastic syndromes MDS who require regular blood transfusions. This Phase 3, randomized, double-blind, placebo-controlled trial aims to find out how well elritercept reduces the need for red blood cell RBC transfusions, especially over longer periods or in adults with high transfusion needs. The study also monitors the safety and tolerability of elritercept. Participants who qualify will be randomly assigned in a 21 ratio to receive either elritercept or a matching placebo by subcutaneous injection every 4 weeks. The study includes a Primary Phase lasting 24 weeks, followed by a Secondary Phase of an additional 24 weeks, during which the same blinded treatment continues. Study visits are scheduled every 2 weeks for the first 6 cycles and every 4 weeks thereafter. An Extension Phase allows eligible participants to continue treatment until they choose to stop or the study is unblinded. Throughout the study, participants will undergo regular assessments including MDS disease evaluations every 24 weeks, laboratory tests, vital sign monitoring, and safety follow-up visits every 4 weeks for 8 weeks after the last dose. Long-term follow-up will continue quarterly for up to 5 years to monitor ongoing health status. The main outcome measured is the percentage of participants achieving transfusion independence for at least 8 weeks during the first 24 weeks of treatment.

Age: 18Years +All GendersPhase 3
182 locations
E

Actively Recruiting

Researchers are studying chronic primary immune thrombocytopenia ITP, a condition where the immune system mistakenly destroys platelets, leading to easier bruising and bleeding due to low platelet counts. The trial aims to evaluate whether mezagitamab, given as a subcutaneous injection, can maintain stable platelet levels in adults with ITP compared to a placebo. This Phase 3 study is randomized, double-blind, and placebo-controlled to thoroughly assess mezagitamabs effects. Participants will receive either mezagitamab or a matching placebo injection once weekly. The dosing schedule includes 8 weeks of weekly injections, followed by an 8-week break, and then another 8 weeks of weekly injections, totaling up to 6 months of treatment. Those who complete this study or do not respond by week 16 may have the option to join a continuation study to receive open-label mezagitamab if eligible. During the study, participants will visit the clinic multiple times for assessments. Researchers will monitor platelet counts regularly and evaluate responses using measures such as the percentage of participants with durable platelet response up to week 24. Additional assessments include symptom questionnaires, fatigue scores, bleeding events, and monitoring of mezagitamab levels and antibodies. The study also observes safety and treatment effects through week 24 and beyond as needed.

Age: 18Years +All GendersPhase 3
124 locations
E

Actively Recruiting

Researchers are evaluating the safety and changes in disease activity of surzetoclax, an investigational oral drug, alone or combined with other treatments in adults with relapsed or refractory multiple myeloma MM, a disease where abnormal plasma cells grow in the bone marrow. This Phase 12 study is designed to find the best doses of surzetoclax in combination with other antimyeloma agents or alone, involving about 325 adult participants worldwide. The study includes multiple substudy phases to explore different drug combinations and dosing schedules for relapsedrefractory MM. Participants will receive surzetoclax with other drugs such as daratumumab given by injection, dexamethasone oral, pomalidomide oral, or etentamig intravenous infusion, depending on the substudy group. The study has dose escalation and optimization phases to determine the best doses of surzetoclax and other agents. Some participants will receive surzetoclax alone, while others receive it combined with other antimyeloma treatments. The total study duration is about 4.5 years. During the study, participants will attend regular visits at approved centers for medical assessments, blood tests, and monitoring of side effects. Researchers will track adverse events and measure disease activity changes. The main outcomes include dose-limiting toxicities and adverse events over up to 4.5 years. Secondary outcomes evaluate response rates, progression-free survival, duration of response, and overall survival. Participants will be closely monitored throughout the study period to assess treatment effects and safety.

Age: 18Years +All GendersPhase 1Phase 2
51 locations

1-10 of 52

1